These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
130 related articles for article (PubMed ID: 39127933)
1. Reprint of: Four-factor prothrombin complex concentrate versus andexanet alfa for direct oral anticoagulant reversal. Koo SJ; Hussain Y; Booth DY; Desai P; Oh ES; Rios J; Audley K J Am Pharm Assoc (2003); 2024; 64(4S):102156. PubMed ID: 39127933 [TBL] [Abstract][Full Text] [Related]
2. Four-factor prothrombin complex concentrate versus andexanet alfa for direct oral anticoagulant reversal. Koo SJ; Hussain Y; Booth DY; Desai P; Oh ES; Rios J; Audley K J Am Pharm Assoc (2003); 2024; 64(2):395-401. PubMed ID: 37952844 [TBL] [Abstract][Full Text] [Related]
3. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhages. Pham H; Medford WG; Horst S; Levesque M; Ragoonanan D; Price C; Colbassani H; Piper K; Chastain K Am J Emerg Med; 2022 May; 55():38-44. PubMed ID: 35272069 [TBL] [Abstract][Full Text] [Related]
4. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis. Costa OS; Connolly SJ; Sharma M; Beyer-Westendorf J; Christoph MJ; Lovelace B; Coleman CI Crit Care; 2022 Jun; 26(1):180. PubMed ID: 35710578 [TBL] [Abstract][Full Text] [Related]
5. Andexanet alfa and four-factor prothrombin complex concentrate for reversal of apixaban and rivaroxaban in patients diagnosed with intracranial hemorrhage. Vestal ML; Hodulik K; Mando-Vandrick J; James ML; Ortel TL; Fuller M; Notini M; Friedland M; Welsby IJ J Thromb Thrombolysis; 2022 Jan; 53(1):167-175. PubMed ID: 34101050 [TBL] [Abstract][Full Text] [Related]
6. Safety, efficacy, and cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with factor Xa inhibitor-related bleeding: a retrospective study. Smith MN; Deloney L; Carter C; Weant KA; Eriksson EA J Thromb Thrombolysis; 2019 Aug; 48(2):250-255. PubMed ID: 30941571 [TBL] [Abstract][Full Text] [Related]
7. The use of andexanet alfa and 4-factor prothrombin complex concentrate in intracranial hemorrhage. Oh ES; Schulze P; Diaz F; Shah K; Rios J; Silverman ME Am J Emerg Med; 2023 Feb; 64():74-77. PubMed ID: 36463661 [TBL] [Abstract][Full Text] [Related]
8. Outcomes Associated With 4-Factor Prothrombin Complex Concentrate Administration to Reverse Oral Factor Xa Inhibitors in Bleeding Patients. Highsmith EA; Morton C; Varnado S; Donahue KR; Sulhan S; Lista A J Clin Pharmacol; 2021 May; 61(5):598-605. PubMed ID: 33094836 [TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Sarode R; Milling TJ; Refaai MA; Mangione A; Schneider A; Durn BL; Goldstein JN Circulation; 2013 Sep; 128(11):1234-43. PubMed ID: 23935011 [TBL] [Abstract][Full Text] [Related]
10. Comparison of 4-factor prothrombin complex concentrate and andexanet alfa for reversal of apixaban and rivaroxaban in the setting of intracranial hemorrhage. Lipski M; Pasciolla S; Wojcik K; Jankowitz B; Igneri LA J Thromb Thrombolysis; 2023 Apr; 55(3):519-526. PubMed ID: 36566473 [TBL] [Abstract][Full Text] [Related]
11. Emergent reversal of oral factor Xa inhibitors with four-factor prothrombin complex concentrate. Lipari L; Yang S; Milligan B; Blunck J Am J Emerg Med; 2020 Dec; 38(12):2641-2645. PubMed ID: 33041150 [TBL] [Abstract][Full Text] [Related]
12. The use of andexanet alfa vs. 4-factor prothrombin complex concentrates in the setting of life-threatening intracranial hemorrhage. Irizarry-Gatell VM; Bacchus MW; De Leo EK; Zhang Y; Lagasse CA; Khanna AY; Harris NS; Zumberg MS Blood Coagul Fibrinolysis; 2024 Apr; 35(3):94-100. PubMed ID: 38358898 [TBL] [Abstract][Full Text] [Related]
13. Four-factor prothrombin complex concentrate plus andexanet alfa for reversal of factor Xa inhibitor-associated bleeding: Case series. Liu J; Elsamadisi P; Philips E; Bauer KA; Eche IM Am J Health Syst Pharm; 2022 Aug; 79(16):1323-1329. PubMed ID: 35291008 [TBL] [Abstract][Full Text] [Related]
14. Real-World Reversal of Factor Xa Inhibition in the Setting of Major Life-Threatening Bleeding or Urgent Surgery. Schmidt LE; Hinton MS; Martin ND J Pharm Pract; 2024 Feb; 37(1):74-79. PubMed ID: 36083782 [No Abstract] [Full Text] [Related]
15. Andexanet Alfa Versus 4-Factor Prothrombin Complex Concentrate for Reversal of Factor Xa Inhibitors in Intracranial Hemorrhage. Ammar AA; Ammar MA; Owusu KA; Brown SC; Kaddouh F; Elsamadicy AA; Acosta JN; Falcone GJ Neurocrit Care; 2021 Aug; 35(1):255-261. PubMed ID: 33403588 [TBL] [Abstract][Full Text] [Related]
16. Andexanet alfa versus PCC products for factor Xa inhibitor bleeding: A systematic review with meta-analysis. White CM; Caroti KS; Bessada Y; Hernandez AV; Baker WL; Dobesh PP; van Haalen H; Rhodes K; Coleman CI Pharmacotherapy; 2024 May; 44(5):394-408. PubMed ID: 38721837 [TBL] [Abstract][Full Text] [Related]
17. Evaluation of andexanet alfa and four-factor prothrombin complex concentrate (4F-PCC) for reversal of rivaroxaban- and apixaban-associated intracranial hemorrhages. J Thromb Haemost; ; . PubMed ID: 32291874 [TBL] [Abstract][Full Text] [Related]